Redeye comments on Lipigon's Q3 report 2023. The main event since our last comment is the applicatio...
Redeye comments on Enviro’s Q3 report, which was very much on the same theme as we saw in Q2, where ...
STENOCARE announced on November 23rd that the company has signed agreements that will make a new pro...
First Venture (”First Venture” eller ”bolaget”) publicerade den 23 november 2023 bolagets delårsrapp...
Under det tredje kvartalet år 2023 fortsatte Windon Energy Group AB (”Windon” eller ”Bolaget”) uppvi...
Turbulens men förstärkt marginal Nettoomsättningen i Q3 uppgick till EUR 3,7 m (5,8 m), fortsatt pr...
Improved gross margin but weak revenue.
Redeye comments on Beyond Frames Q3 2023 report, showing higher sales than expected but slightly low...
Redeye comments on Fragbite Groups Q3’23 report, showing stronger sales than expected and profitabil...
We hosted CEO Olle Svensk for our Investor Days seminar on 22/11 Continued growth in DTC (~30% y-o-y...
Taaleri hosted its capital markets day yesterday. The event did not offer any large surprises after ...
Redeye updates its view on Flexion Mobile following its Q3 2023 report.
Redeye provides an update in relation to ISAB’s Q3 2023 report.
Fortsatt tillväxt i läkemedelsportföljen EQL Pharma rapporterade en tillväxt om 16,4 procent för de ...
On November 22nd, Eevia Health published the company’s quarterly report for Q3-23.
Redeye comments on the news yesterday that Carasent’s subsidiary, Metodika EPM signed, a contract wi...
Zoomability Int AB publicerade den 22 november 2023 bolagets delårsrapport för årets tredje kvartal.
Redeye comments on the postponement of the game Warhammer 40,000: Space Marine 2, now expected to be...
Focus in 2024e is on growth... ...while maintaining current EBITA margins amid operational leverage ...
Redeye comments on Heliospectra’s bride loan, announced last evening.
